Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


More On

Borden leads Cooley team in Horizon Pharma’s acquisition of Vidara Therapeutics

The deal, expected to close by mid-2014, positions the company for future acquisitions

Cooley LLP's M&A head Barbara L. Borden

When Horizon Pharma Inc. acquired Vidara Therapeutics International Ltd. for $660 million, it tapped Cooley and its M&A head Barbara L. Borden to spearhead the deal.

Borden’s team included partners Kay Chandler, Sean Clayton, Mark Hrenya and Mischi a Marca; special counsel Barry Graynor, Eric Kauffman and Michelle Lara; and associates Wade Andrews, Ben Beerle, Scott Tanner and Matt Robbins. Partner Jackie Grise (antitrust); partner Natasha Leskovsek (life sciences); of counsel John Steines and associate Michael Baker (tax) provided critical support, according to the firm.

“It was an extremely complex deal, and it was done within a really short time frame,” Borden told WIPL Network. “This is a client I particularly like working with, so that makes it more fun.”

Horizon Pharma is based in Deerfield, Ill., and Vidara is a specialty pharmaceutical company with operations in Dublin, Ireland and the United States. The new company will be organized under the laws of Ireland, which presented interesting challenges during acquisition talks, Borden said. The resulting company will have a portfolio of four products marketed primarily in the United States. The deal, expected to close by mid-2014, positions the company for future acquisitions.

Borden, resident in Cooley’s San Diego office, specializes in mergers and acquisitions, cross-border transactions, joint ventures and other complex transactions and public securities law. She represents strategic and financial buyers and sellers in public and private acquisitions.

Borden said she was attracted to M&A because she enjoys negotiations and likes puzzles. “Deals have a complexity and are like a chess game,” she said. “Successful deals require knowledge about how all the pieces interact, and people can lose track of that.” M&A deals also require a cross-disciplinary aspect, and Borden said she enjoys working with specialists in other practice areas.

Contributing Author

author image

Amy I. Stickel

Amy I. Stickel has extensive experience covering the legal, financial and pharmaceutical industries as a writer and editor. A past managing editor of Corporate Legal Times and...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.